Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Mallinckrodt plc | EVP & Chief Scientific Officer | Restricted Stock Units | 10.3K | Feb 2, 2024 | Direct | ||
ANTARES PHARMA, INC. | EVP, Research and Development and Chief Medical Officer | Common Stock | 0 | $5.60 | May 24, 2022 | Direct | |
ANTARES PHARMA, INC. | EVP, Research and Development and Chief Medical Officer | Stock Option (right to buy) | 0 | May 24, 2022 | Direct | ||
Mallinckrodt plc | EVP & Chief Scientific Officer | Ordinary Shares | 0 | $37.50 | Nov 14, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
NONE | Mallinckrodt plc | Feb 2, 2024 | 1 | $0 | 4 | Feb 6, 2024 | EVP & Chief Scientific Officer |
MNKTQ | Mallinckrodt plc | Nov 14, 2023 | 1 | $0 | 4 | Nov 16, 2023 | EVP & Chief Scientific Officer |
MNK | Mallinckrodt plc | Jun 30, 2023 | 1 | $0 | 4 | Jul 5, 2023 | EVP & Chief Scientific Officer |
MNK | Mallinckrodt plc | Apr 3, 2023 | 1 | $0 | 4 | Apr 5, 2023 | EVP & Chief Scientific Officer |
MNK | Mallinckrodt plc | Feb 2, 2023 | 1 | $0 | 4 | Feb 3, 2023 | EVP & Chief Scientific Officer |
MNK | Mallinckrodt plc | Jan 12, 2023 | 0 | $0 | 3 | Jan 20, 2023 | EVP & Chief Scientific Officer |
ATRS | ANTARES PHARMA, INC. | May 24, 2022 | 4 | -$283K | 4 | May 26, 2022 | EVP, Research and Development and Chief Medical Officer |
ATRS | ANTARES PHARMA, INC. | Jun 10, 2021 | 2 | $160K | 4 | Jun 14, 2021 | EVP, R&D Chief Medical Officer |